• Overview
    • Stock Information
    • Press Releases
    • Corporate Presentation
    • SEC Filings and Financials
      • SEC Filings
    • Events
    • Management Team
    • Corporate Governance
    • Analyst Coverage
    • FAQs
    • Information Request
Checkpoint Therapeutics
  • Home
  • About Us
    • Management Team
    • Board of Directors
  • Pipeline
    • CK-101 EGFR Inhibitor
    • CK-301 Anti-PD-L1
    • CK-103 BET Inhibitor
    • CK-302 Anti-GITR
    • Anti-CAIX
    • Publications
  • Business Development
  • Investors & Media
    • Overview
    • Stock Information
    • Press Releases
    • Corporate Presentation
    • SEC Filings and Financials
      • SEC Filings
    • Events
    • Management Team
    • Corporate Governance
    • Analyst Coverage
    • FAQs
    • Information Request
  • Contact Us

Information Request

Email Alert Social media sharing
To join our mailing list, please complete your contact information and email address below. If you have any questions or comments, please submit your request to ir@checkpointtx.com
First Name *
 
Last Name *
 
Email Address *
 
Institution
 
Enter the code shown above.
 
Copyright ,  © Powered By Q4 Inc.
  • 2 Gansevoort Street
  • 9th Floor
  • New York, NY 10014
  • 781-652-4500
  • info@checkpointtx.com
  • © Copyright 2020 Checkpoint Therapeutics, Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap
REQUEST A MEETING WITH MANAGEMENT